Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PSMB8 | P28062 | 1/20 | 0.69 |
| ▸ | NOS3 | P29474 | 3/20 | 0.54 |
| ▸ | NOS1 | P29475 | 3/20 | 0.54 |
| ▸ | NOS2 | P35228 | 3/20 | 0.54 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.54 |
| ▸ | GRIA2 | P42262 | 1/20 | 0.54 |
| ▸ | GRIA3 | P42263 | 1/20 | 0.54 |
| ▸ | GRIA4 | P48058 | 1/20 | 0.54 |
| ▸ | LMNA | P02545 | 1/20 | 0.54 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.54 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.54 |
| ▸ | TSHR | P16473 | 1/20 | 0.54 |
| ▸ | THPO | P40225 | 1/20 | 0.54 |
| ▸ | BLM | P54132 | 1/20 | 0.54 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.54 |
| ▸ | PARP1 | P09874 | 1/20 | 0.49 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.47 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.47 |
| ▸ | DAO | P14920 | 1/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31187650 | 1.00 | PSMB8 (0.69) | PSMB8NOS3NOS1NOS2GRIA1 | |
| SCHEMBL217228 | 0.86 | NOS1 (0.54) | PSMB8NOS1GRIA1GRIA2GRIA3 | |
| SCHEMBL30278461 | 0.81 | PSMB8 (1.00) | PSMB8NOS1GRIA1GRIA2GRIA3 | |
| SCHEMBL2074264 | 0.81 | PSMB8 (1.00) | PSMB8NOS1GRIA1GRIA2GRIA3 | |
| SCHEMBL3813431 | 0.80 | PARP1 (0.54) | PSMB8GRIA1GRIA2GRIA3GRIA4 | |
| SCHEMBL2062395 | 0.80 | PARP1 (0.58) | PSMB8GRIA1GRIA2GRIA3GRIA4 | |
| SCHEMBL31110228 | 0.80 | PARP1 (0.58) | PSMB8GRIA1GRIA2GRIA3GRIA4 | |
| SCHEMBL29530378 | 0.77 | CA12 (0.58) | GRIA1GRIA2GRIA3GRIA4LMNA | |
| SCHEMBL870661 | 0.77 | CA12 (0.58) | GRIA1GRIA2GRIA3GRIA4LMNA | |
| SCHEMBL6541777 | 0.74 | PGR (0.58) | PSMB8NOS1PDE3BPDE3APOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 121 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117736159-A | Preparation method of chlorzoxazone | 九江善水科技股份有限公司 | 2024-03-22 | — | — | CN | claimed |
| CN-106866449-A | A kind of method that the acetyl-anisidine of 2 amino 4 is prepared using 2,4 dinitrophenol hydrogenating reduction by-product recoveries | 九江善水科技股份有限公司 | 2017-06-20 | — | — | CN | claimed |
| US-20260062416-A1 | INHIBITORS OF KIF18A AND USES THEREOF | ACCENT THERAPEUTICS INC (US) | 2026-03-05 | — | — | US | disclosed |
| US-20240327390-A1 | SUBSTITUTED NITROGEN CONTAINING COMPOUNDS | BRISTOL MYERS SQUIBB CO (US) | 2024-10-03 | — | — | US | disclosed |
| EP-3929194-B1 | SUBSTITUTED NITROGEN CONTAINING COMPOUNDS | BRISTOL MYERS SQUIBB CO (US) | 2024-04-17 | — | — | EP | disclosed |
| CN-117736159-A | Preparation method of chlorzoxazone | 九江善水科技股份有限公司 | 2024-03-22 | — | — | CN | disclosed |
| WO-2024035950-A1 | INHIBITORS OF KIF18A AND USES THEREOF | ACCENT THERAPEUTICS, INC. (US) | 2024-02-15 | — | — | WO | disclosed |
| WO-2024030651-A1 | GPX4 INHIBITORS AND USE THEREOF | SONATA THERAPEUTICS, INC. (US) | 2024-02-08 | — | — | WO | disclosed |
| US-RE49700-E1 | Substituted nitrogen containing compounds | BRISTOL-MYERS SQUIBB COMPANY (US) | 2023-10-17 | — | — | US | disclosed |
| US-RE49700-E1 | Substituted nitrogen containing compounds | BRISTOL-MYERS SQUIBB COMPANY (US) | 2023-10-17 | — | — | US | disclosed |
| US-RE49700-E1 | Substituted nitrogen containing compounds | BRISTOL-MYERS SQUIBB COMPANY (US) | 2023-10-17 | — | — | US | disclosed |
| EP-0477819-B1 | Benzimidazole derivatives, their preparation and use | NEUROSEARCH AS (DK) | 1995-03-15 | — | — | EP | disclosed |
| US-5200422-A | Benzimidazole derivatives, their preparation and use | NEUROSEARCH A/S (DK) | 1993-04-06 | — | — | US | disclosed |
| EP-0477819-A2 | Benzimidazole derivatives, their preparation and use | NEUROSEARCH A/S (DK) | 1992-04-01 | — | — | EP | disclosed |
| US-4873338-A | Process for the preparation of 2-amino-5-acylamino phenols and starting compounds suitable therefor | AGFA-GEVAERT AKTIENGESELLSCHAFT (DE) | 1989-10-10 | — | — | US | disclosed |
| EP-0075533-B1 | HEAT-CURABLE EPOXY-RESIN COMPOSITIONS | CIBA-GEIGY AG (CH) | 1985-08-07 | — | — | EP | disclosed |
| US-4404356-A | USING A 2-HYDROXYPHENYL UREA AS CORING AGENT; STORAGE STABILITY; CASTINGS; MOLDING MATERIALS | CIBA-GEIGY CORPORATION (US) | 1983-09-13 | — | — | US | disclosed |
| EP-0075533-A1 | Heat-curable epoxy-resin compositions | CIBA-GEIGY AG (CH) | 1983-03-30 | — | — | EP | disclosed |
| US-4377695-A | ANTIINFLAMMATORY, ANALGESIC, ANTICOAGULANT AGENTS | A. NATTERMANN & CIE GMBH (DE) | 1983-03-22 | — | — | US | disclosed |
| EP-0051827-A1 | Omega-(2-oxo-benzimidazolinyl)-alkanoic acid derivatives, process for producing the same and pharmaceutical compounds containing the same | A. Nattermann & Cie. GmbH (DE) | 1982-05-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240327390-A1 | SUBSTITUTED NITROGEN CONTAINING COMPOUNDS | NR0B1, GRK1, GRIN1 | PSMB8 2954/4885NOS3 289/4885NOS1 165/4885 |
| US-20260062416-A1 | INHIBITORS OF KIF18A AND USES THEREOF | KIF18A, KIF18B, KIF5B | PSMB8 887/4885NOS3 4383/4885NOS1 4418/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.